EFTR (eFFECTOR Therapeutics) Earnings per share growth rate in current year

Official company branding of eEFFECTOR (EFTR)

eFFECTOR Therapeutics (EFTR) develops selective protein translation regulators for lung cancer therapy, securing monopoly revenues through patents. The annual EPS growth rate clearly demonstrates the impact of the production and testing outsourcing model. However, the failure of clinical trials and the liquidation of the business have eliminated all defensive barriers. The value of 62.00 is the current reading of this metric, capturing the company's final development trajectory.

EFTR (eFFECTOR Therapeutics) Earnings growth in current year history from 07/04/2022 to 08/04/2024

Financial and market metric breakdowns for eFFECTOR Therapeutics (EFTR)

- price and consensus price forecast:
Stock Quotes eEFFECTOR Therapeutics, Inc.|EFTR - Analyst Consensus Forecast
- business market valuation indicators:
Market Value eEFFECTOR Therapeutics, Inc.|EFTR - Total Company Value
- balance sheet equity data:
Accounting Value of a Share eEFFECTOR Therapeutics|EFTR - Book Capitalization|Market-to-Book Ratio effector.com|EFTR - Company Total Assets
- debt and liquidity details:
Aggregate Debt to Equity eFFECTOR Therapeutics|EFTR - Long-Term Debt to Capital|Current Liabilities to Equity effector.com|EFTR - Company Aggregate Debts|Debts to Book Value eEFFECTOR Therapeutics, Inc.|EFTR - Company Long-Term Debts|Company Current Liabilities eEFFECTOR Therapeutics|Intermediate Liquidity Ratio effector.com
- net income and valuation multiples indicators:
EFTR - Company Net Income|Expected Net Profit eFFECTOR Therapeutics|EFTR - Price to Earnings Ratio|Future Price to Earnings Multiple eEFFECTOR|EFTR - Price/Earnings to Growth Multiple|Business Value to Operating Income Before Depreciation eEFFECTOR Therapeutics, Inc.|EFTR - Operating profit before deduction of amortization|Earnings per share for the last four quarters eEFFECTOR Therapeutics|EFTR - Net earnings per share (EPS TTM)|Year-over-year earnings per one share growth for the last 12 months effector.com|EFTR - Earnings growth in current year|Expected net earnings per share growth next year eFFECTOR Therapeutics
Fundamental valuation:EFTR eEFFECTOR Therapeutics, Inc.
Product sample of eEFFECTOR

This metric measures the year-over-year growth rate of net earnings per share, reflecting the efficiency of capital generation. By analyzing the annual change in earnings per share, an investor can compare the market value of eFFECTOR Therapeutics (EFTR) with its financial statements. The absence of in-house facilities due to production outsourcing allows the company to optimize costs, which directly impacts the dynamics of this metric.

Direct competitors

Net earnings per share growth this year ArriVent Corp|LTRN (Lantern Pharma Inc) - Earnings growth in current year|Earnings per share growth rate in current year bioAffinity BIAF